Macrophage TBK1 signaling drives the development and outgrowth of breast cancer brain metastasis

F Fatima Khan (Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic) Y Yang Liu D Donovan Whitfield (Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic) L Lizhi Pang (Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic) H Heba Ali (Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University) Y Yuyun Huang (Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic) F Fei Zhou R Robert S. Hagan (Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill) K Katie Frenis (Department of Hematology, Boston Children’s Hospital) R R. Grant Rowe (Department of Hematology, Boston Children’s Hospital) P Peiwen Chen (Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic)

Abstract

Tumor-associated macrophages (TAMs) are the predominant immune cells in the tumor microenvironment that promote breast cancer brain metastasis (BCBM). Here, we identify TANK-binding kinase (TBK1) as a critical signaling molecule enriched and activated in TAMs of BCBM tumors, playing an indispensable role in BCBM development and metastatic outgrowth in the brain. Mechanistically, BCBM cell-secreted matrix metalloproteinase 1 binds to protease-activated receptor 1 and integrin αVβ5 on macrophages, leading to TBK1 activation mediated by the nuclear factor-kappa B pathway. Reciprocally, TBK1-regulated TAMs produce granulocyte-macrophage colony-stimulating factor (GM-CSF) to drive breast cancer cell epithelial–mesenchymal transition, migration, and invasion, ultimately contributing to BCBM development and brain metastatic outgrowth. Inhibition of TBK1 signaling in TAMs or GM-CSF receptor in cancer cells impedes BCBM development and brain metastatic outgrowth. Correspondingly, the TBK1–GM-CSF signaling axis correlates with lower overall survival in patients with BCBM. Thus, TBK1-mediated tumor-TAM symbiotic interaction provides a promising therapeutic target for patients with BCBM.

Article Details

Volume / Issue Vol. 122, Issue 34
Published August 26, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (11)

F

Fatima Khan

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic

Y

Yang Liu

D

Donovan Whitfield

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic

L

Lizhi Pang

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic

H

Heba Ali

Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University

Y

Yuyun Huang

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic

F

Fei Zhou

R

Robert S. Hagan

Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill

K

Katie Frenis

Department of Hematology, Boston Children’s Hospital

R

R. Grant Rowe

Department of Hematology, Boston Children’s Hospital

P

Peiwen Chen

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic